Application of Dcaf10 as drug target in preparation of drug for preventing and treating obesity fatty liver

By overexpressing the Dcaf10 gene as a drug target, the problem of unknown function of Dcaf10 was solved, and the effect of improving obese fatty liver was achieved, providing an important reference for the clinical prevention and treatment of obese fatty liver and drug development.

CN118903429AActive Publication Date: 2024-11-08ANHUI AGRICULTURAL UNIVERSITY +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411038589.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-08
Estimated Expiration
2044-07-31

AI Technical Summary

Technical Problem

It is unclear about the function of the Dcaf10 gene, and how to develop the purpose of this gene to prepare drugs to prevent and treat obese fatty liver.

Method used

Using the Dcaf10 gene as a drug target, screen drugs that improve obese fatty liver by constructing in vitro cell models or animal models of Dcaf10 gene overexpression, and use Dcaf10 overexpression reagents or reagents that promote Dcaf10 overexpression, including those containing the Dcaf10 gene. Viral overexpression vector, liver-specific overexpression is performed to improve obese fatty liver.

Benefits of technology

It was first discovered that Dcaf10 has the function of improving obese fatty liver. After knockout of Dcaf10 gene, it significantly aggravates obese fatty liver. However, the specific overexpression of Dcaf10 by the liver can significantly improve the symptoms of obese fatty liver, providing important clinical prevention and treatment and drugs. R&D reference value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903429A_ABST
    Figure CN118903429A_ABST
Patent Text Reader

Abstract

The invention discloses application of Dcaf10 as a drug target in preparation of drugs for preventing and treating obesity fatty liver, and belongs to the technical field of biological drugs. The Dcaf10 gene serves as a drug target, an in-vitro cell model or an animal model over-expressed by the Dcaf10 gene is constructed and used for screening drugs and / or biological reagents for improving the obese fatty liver, and the purpose of improving the obese fatty liver is achieved through a gene engineering technology. The application has the beneficial effects that the obesity fatty liver can be obviously aggravated after the Dcaf10 gene is knocked out for the first time. For the obesity fatty liver caused by the Dcaf10 gene knockout, AAV8-Albgt is given to the obesity fatty liver caused by the Dcaf10 gene knockout; after the mDcaf10 is subjected to liver specific overexpression, the symptom of the obesity fatty liver can be obviously improved. The discovery has important reference value for clinical treatment and drug research and development of the obesity fatty liver disease, can be prepared into a biological preparation for preventing and treating the obesity fatty liver disease, and has popularization and application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biological medicines, and in particular to application of Dcaf10 as a drug target in the preparation of drugs for preventing and treating obesity-related fatty liver. Background Art

[0002] In vivo, the ubiquitin-proteasome system (UPS) is widely involved in regulating various life activities of cell growth and development. The UPS consists of four main components: ubiquitin, ubiquitin ligase, proteasome and deubiquitinating enzymes (DUBs). DCAFs family proteins usually form E3 ubiquitin ligases together with CRL4 and DDB1. At present, the function of Dcaf10 gene has not been reported. For a long time, people have been curious about whether DDB1 directly binds to substrates or recruits substrates through substrate-binding proteins. Recent work has identified a class of proteins containing WD40 repeat sequences as substrate-binding proteins through tandem affinity purification and immunoprecipitation techniques. They are called DDB1-CUL4 associated factors (DCAF) or DWD proteins. They directly interact with the BPA and BPC domains of DDB1. Their main function is to assist the E3 ubiquitin ligase complex to recruit different substrates through interactions to exert different biological functions.

[0003] More than 60 DCAF molecules have been identified so far, 52 of which contain WD40 domains. The WD40 domain is composed of more than 4 WD40 repeats. Each WD40 repeat contains a conserved center of about 40 to 60 amino acids, usually ending with tryptophan-aspartic acid (WD), so this type of protein is named WD40 protein. In most cases, the N-terminus of each WD40 repeat starts with glycine-histidine (GH) and ends with tryptophan-aspartic acid (WD) at the C-terminus. The WD40 repeat is usually followed by a single non-conserved amino acid or a conserved arginine residue, so it is also called the "WDXR" motif. DCAF family proteins recognize and interact with DDB1 through the "WDXR" motif to form a complex. The conserved core between the repeated GH and WD together forms a stable β-propeller structure. Unlike DDB 1, which has three β-propeller domains, DCAF contains only one β-propeller domain. Generally, a typical β-propeller domain contains 7-8 β-blades, each blade is composed of 4 antiparallel β-strands, forming a hollow barrel-shaped β-propeller. The polar amino acid residues at the top and bottom of the β-propel ler are usually the active sites for the interaction of WD40 protein with other proteins. The different hydrophobicity, charge and steric hindrance on the surface of the structure of WD40 protein determine its recruitment of different substrate proteins.

[0004] In terms of function, DCAF family proteins usually form E3 ubiquitin ligases together with CRL4 and DDB1 to ubiquitinate target proteins. DCAF family proteins are widely involved in regulating various life activities such as cell growth, development, differentiation, apoptosis, and are closely related to the occurrence and progression of a series of diseases such as tumors and developmental disorders. The main functions of DCAF family proteins are shown in the following table:

[0005] DCAFs Gene ID Function <![CDATA[DCAF1 / VprBP ]]> 9730 <![CDATA[Cytoplasmic retention of HIV-1 VpR ;p53]]> DCAF2 / CDT2 51514 p21 ubiquitination DCAF3 / AMBRA 55626 Regulates BECLIN1-dependent autophagy DCAF4 26094 Associated with leucocyte telomere length DCAF5 8816 SOX2 ubiquitination DCAF6 / NRIP / IQWD1 55827 Steroid receptor coactivator DCAF7 / WDR68 10238 Maintains normal levels of DYRK1A DCAF8 50717 Unknown DCAF9 / WDTC1 23038 E3 ubiquitin ligase complex DCAF10 / WDR32 79296 Unknown DCAF11 / WDR23 80344 SLBP ubiquitination DCAF12 / WDR40A 25853 Unknown DCAF13 / WDSOFl 25879 Ribosome maturation DCAF14 / PHIP 55023 10q26 defective syndrome DCAF15 90379 <![CDATA[ Indisulam induced RBM39 ubiquitination]]> DCAF16 54876 Unknown DCAF17 80067 Gonadal development

[0006] However, the function of Dcaf10 is still unclear.

[0007] The Chinese patent application document with publication number CN111621561A discloses an application of OLFM4 in non-alcoholic fatty liver disease (NAFLD), specifically including the application of OLFM4 in the preparation of NAFLD detection reagents and the application of OLFM4 in the preparation of NAFLD therapeutic drugs. The change in OLFM4 expression has a regulatory effect on NAFLD. If the therapeutic drug contains a human OLFM4 sequence recombinant protein that specifically upregulates liver OLFM4 expression, it can alleviate liver steatosis in NAFLD patients. The patent discloses the research method and application of OLFM4 in NAFLD, which facilitates in-depth analysis of the role of OLFM4 in NAFLD. At the same time, the application of this technical solution facilitates the elucidation of the mechanism of action of OLFM4 and provides a new perspective for the study of OLFM4. However, the patent does not involve the application of the Dcaf10 gene in obese fatty liver. Summary of the invention

[0008] The technical problem to be solved by the present invention is that the function of the Dcaf10 gene is still unclear, and how to develop the use of the gene.

[0009] The present invention solves the above technical problems through the following technical means:

[0010] The present invention proposes the use of Dcaf10 as a drug target in the preparation of a drug for preventing and treating obesity-related fatty liver.

[0011] Beneficial effects: The present invention first discovered that Dcaf10 has the function of improving obese fatty liver. This discovery is of great significance for the clinical prevention and treatment of obese fatty liver, and can be made into a biological preparation to improve obese fatty liver, which has the value of promotion and application.

[0012] Preferably, the Dcaf10 includes the Dcaf10 gene and the Dcaf10 protein.

[0013] Preferably, the nucleotide sequence of the Dcaf10 gene is as shown in SEQ ID NO:1.

[0014] Preferably, the drug includes a Dcaf10 overexpression agent or an agent that promotes Dcaf10 overexpression.

[0015] Preferably, the Dcaf10 overexpression reagent includes a viral overexpression vector containing the Dcaf10 gene or a virus containing the Dcaf10 gene.

[0016] Preferably, the virus containing the Dcaf10 gene includes a lentivirus containing the Dcaf10 gene or an adenovirus containing the Dcaf10 gene.

[0017] Preferably, the Dcaf10 gene is used as a drug target to construct an in vitro cell model or animal model with overexpression of the Dcaf10 gene, which is used to screen drugs and / or biological agents for improving obese fatty liver, thereby achieving the purpose of improving obese fatty liver through genetic engineering technology.

[0018] Preferably, the obesity-induced fatty liver includes: simple hepatic fatty liver degeneration, non-alcoholic steatohepatitis, and liver fibrosis.

[0019] The present invention also provides a drug for improving obese fatty liver, which comprises a Dcaf10 overexpression agent or a agent that promotes Dcaf10 overexpression.

[0020] Preferably, the Dcaf10 overexpression reagent includes a viral overexpression vector containing the Dcaf10 gene or a virus containing the Dcaf10 gene.

[0021] The advantages of the present invention are:

[0022] 1. The present invention first discovered that Dcaf10 has the function of improving obese fatty liver. This discovery is of great significance for the clinical prevention and treatment of obese fatty liver, and can be made into a biological preparation to treat obese fatty liver disease, which has the value of promotion and application.

[0023] 2. The present invention first discovered that Dcaf10 gene knockout can significantly aggravate obese fatty liver. For obese fatty liver caused by Dcaf10 gene knockout, liver-specific overexpression of AAV8-Alb>mDcaf10 can significantly improve the symptoms of obese fatty liver. This discovery has important reference value for the clinical prevention and treatment of obese fatty liver and drug development, and can be made into a biological preparation to treat obese fatty liver, which has promotion and application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 The Dcaf10 gene knockout group mice showed symptoms of obesity and hyperlipidemia, where A is a representative diagram of mouse obesity; B is a statistical diagram of mouse weight; C is a statistical diagram of mouse fat mass; D is a statistical diagram of serum total cholesterol; E is a statistical diagram of total triglyceride content / g protein in the liver;

[0025] Figure 2 The liver hypertrophy of mice after Dcaf10 gene knockout, where A is a representative diagram of liver hypertrophy; B is a statistical diagram of liver weight; C is a statistical diagram of the ratio of liver weight to body weight;

[0026] Figure 3 HE staining images of liver, A is HE staining image of liver in WT+LF group; B is Dcaf10 - / - HE staining of liver in the +LF group; C is HE staining of liver in the WT+HF group; D is Dcaf10- / - + HF group liver HE staining;

[0027] Figure 4 Liver-specific overexpression of Dcaf10 improved Dcaf10 - / - Obesity and dyslipidemia of mice, where A is the weight of mice in each group; B is the fat weight of mice in each group; C is the total cholesterol content of mice in each group; D is the statistical graph of total triglyceride content / g protein in the liver of mice in each group;

[0028] Figure 5 Liver-specific overexpression of Dcaf10 improved Dcaf10 - / - Mouse liver hypertrophy, where A is a representative picture of the liver of each group of mice; B is a statistical chart of the liver weight of each group of mice. DETAILED DESCRIPTION

[0029] In order to make the purpose, technical solutions and advantages of the present invention easier to implement clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0030] Unless otherwise specified, the test materials and reagents used in the following examples can be obtained from commercial sources.

[0031] If no specific techniques or conditions are specified in the examples, they can be carried out according to the techniques or conditions described in the literature in the art or according to the product instructions.

[0032] Embodiment 1:

[0033] The present invention firstly knocked out Dcaf10 systemically in C57BL / 6J mice (male, 6 weeks old, from Anhui Agricultural University) by homologous recombination technology. The mice were raised in the SPF animal room of Anhui Agricultural University, and 6-week-old male mice were selected for the experiment. The experimental mice were divided into WT wild type and Dcaf10 gene knockout (Dcaf10 - / - ) group, which were given 10% low-fat feed (TP23302) and 80% high-fat feed (TP23300) (the feed was purchased from Nantong Trophy Feed Technology Co., Ltd.), and were divided into WT+LF, WT+HF, Dcaf10 - / - +LF, Dcaf10 - / - +HF (WT+LF is the wild-type mice low-fat diet group; WT+LF is the wild-type mice high-fat diet group; Dcaf10 - / -+LF is the low-fat diet group of Dcaf10 knockout mice; Dcaf10 - / - +HF is a high-fat diet group for Dcaf10 knockout mice), 8 mice in each group, and the feeding intervention lasted for 12 weeks. We found that after systemic knockout of Dcaf10, mice developed obesity and NAFLD. ( Figure 1 ),from Figure 1 It can be seen that mice in the Dcaf10 knockout group showed obesity and increased fat mass. Figure 1 Dcaf10 in AB - / - +LF、Dcaf10 - / - The body weight of mice in the +HF group was significantly greater than that in the WT+LF and WT+HF groups; Figure 1 C in Dcaf10 - / - +LF、Dcaf10 - / - The fat weight of mice in the +HF group was significantly greater than that in the WT+LF and WT+HF groups; Figure 1 DE in Dcaf10 - / - +LF、Dcaf10 - / - The serum total TC and liver TG contents in the +HF group were significantly higher than those in the WT+LF and WT+HF groups. # P<0.05, significant difference, ### P<0.05, the difference is extremely significant; compared with the WT group, the Dcaf10 knockout group * P<0.05, significant difference, ** P<0.01, the difference is extremely significant. * P<0.001, the difference is extremely significant.)

[0034] like Figure 2 As shown in the figure, mice in the Dcaf10 knockout group had liver hypertrophy and increased liver-to-weight ratio. Figure 2 Dcaf10 in AB - / - +LF、Dcaf10 - / - The liver mass of mice in the +HF group was significantly greater than that in the WT+LF and WT+HF groups. ### P<0.05, the difference is extremely significant; compared with the WT group, the Dcaf10 knockout group * P<0.05, significant difference, * P<0.001, the difference is extremely significant.

[0035] like Figure 3 As shown, the area of ​​fatty infiltration in the liver of mice with Dcaf10 gene knockout was increased. - / - The fatty infiltration area of ​​the liver in the +LF group was larger than that in the WT+LF group.- / - The area of ​​fatty infiltration in the liver of mice in the +HF group was larger than that in the WT+HF group.

[0036] In addition, we further explored the therapeutic function of Dcaf10 on obese fatty liver and found that the obese fatty liver caused by Dcaf10 gene knockout can be significantly improved after administration of AAV8 virus serum and Alb liver-specific liver overexpression of Dcaf10. The experimental method is as follows: First, C57BL / 6J mice were systemically knocked out by Dcaf10. The experimental mice were divided into wild-type, Dcaf10 gene knockout group and Dcaf10 liver-specific overexpression group, and were given 10% low-fat feed (TP23302) and 80% high-fat feed (TP23300) (feed purchased from Nantong Trofi Feed Technology Co., Ltd.) diets, and the specific groups were WT+LF, WT+HF, Dcaf10 - / - +LF / EGFP, Dcaf10 - / - +HF / EGFP, Dcaf10 - / - +Alb>mDcaf10 / LF,Dcaf10 - / - +Alb>mDcaf10 / HF(Dcaf10 - / - +LF / EGFP is the Dcaf10 whole body knockout empty vector control low-fat diet group, Dcaf10 - / - +HF / EGFP is the Dcaf10 whole body knockout empty vector control high fat diet group, Dcaf10 - / - +Alb>mDcaf10 / LF is the Dcaf10 systemic knockout, liver-specific overexpression, and low-fat diet group. - / - +Alb>mDcaf10 / HF (Dcaf10 knockout, liver-specific overexpression, high-fat diet group), 10 mice in each group, and the feeding intervention lasted for 12 weeks. The mice in the Alb>mDcaf10 group were injected with AAV8+Alb>mDcaf10 (dose: 2.5×10 11 GC), while the EGFP group mice were injected with the same dose of AAV8+Alb-EGFP via tail vein at 5 and 10 weeks of age. We found that after systemic knockout of Dcaf10, mice developed obese fatty liver, and after liver-specific overexpression of Dcaf10, the obese fatty liver induced by systemic knockout of Dcaf10 was significantly improved. (e.g. Figure 4 As shown in the figure, it can be seen that liver-specific overexpression of Dcaf10 can significantly inhibit the symptoms of obesity-induced fatty liver caused by systemic gene knockout of Dcaf10. Figure 4 AB shows that Dcaf10 - / -+Alb>mDcaf10 / LF、Dcaf10 - / - The body weight and fat weight of mice in the +Alb>mDcaf10 / HF group were significantly lower than those in the Dcaf10 - / - +LF / EGFP and Dcaf10 - / - +HF / EGFP group; analysis Figure 4 CD shows that Dcaf10 - / - The levels of serum TC and liver TG in mice in the +Alb>mDcaf10 / HF group were significantly lower than those in the Dcaf10 - / - +HF / EGFP group. )

[0037] like Figure 5 As shown in the figure, it can be seen that liver-specific overexpression of Dcaf10 can significantly inhibit the symptoms of obesity-induced fatty liver caused by systemic gene knockout of Dcaf10. Figure 5 AB shows that Dcaf10 - / - +Alb>mDcaf10 / LF、Dcaf10 - / - The liver size of mice in the +Alb>mDcaf10 / HF group was significantly smaller than that in the Dcaf10 - / - +LF / EGFP and Dcaf10 - / - +HF / EGFP group.

[0038] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some of the technical features may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. Application of Dcaf10 as a drug target in the preparation of drugs for the prevention and treatment of obesity-related fatty liver.

2. The use according to claim 1, It is characterized in that The Dcaf10 includes the Dcaf10 gene and the Dcaf10 protein.

3. The use according to claim 1, It is characterized in that The nucleotide sequence of the Dcaf10 gene is shown in SEQ ID NO:

1.

4. The use according to claim 1, It is characterized in that The drug includes a Dcaf10 overexpression agent or an agent that promotes Dcaf10 overexpression.

5. The use according to claim 1, It is characterized in that The Dcaf10 overexpression reagent includes a virus overexpression vector containing the Dcaf10 gene or a virus containing the Dcaf10 gene.

6. The use according to claim 1, It is characterized in that The virus containing the Dcaf10 gene includes a lentivirus containing the Dcaf10 gene or an adenovirus containing the Dcaf10 gene.

7. The use according to claim 1, It is characterized in that The Dcaf10 gene is used as a drug target to construct an in vitro cell model or animal model with overexpression of the Dcaf10 gene, which is used to screen drugs and / or biological agents for improving obese fatty liver, so as to achieve the purpose of preventing and treating obese fatty liver through genetic engineering technology.

8. The use according to claim 1, It is characterized in that The obesity-induced fatty liver includes simple fatty liver degeneration and non-alcoholic fatty liver hepatitis.

9. A drug for treating fatty liver caused by obesity, It is characterized in that It includes a Dcaf10 overexpression agent or an agent that promotes Dcaf10 overexpression.

10. The drug according to claim 9, It is characterized in that The Dcaf10 overexpression reagent includes a virus overexpression vector containing the Dcaf10 gene or a virus containing the Dcaf10 gene.

Citation Information

Patent Citations

  • Application of OLFM4 (Olfactomedin-4) to nonalcoholic fatty liver disease (NAFLD)

    CN111621561A